<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03773744</url>
  </required_header>
  <id_info>
    <org_study_id>Ad/MG1-MAGEA3-003</org_study_id>
    <nct_id>NCT03773744</nct_id>
  </id_info>
  <brief_title>MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma</brief_title>
  <acronym>Pelican</acronym>
  <official_title>A Phase 1b, Multicenter, Open-label Trial of Oncolytic MG1 Expressing MAGE-A3 (MG1-MAGEA3) With Adenovirus Vaccine Expressing MAGE-A3 (Ad-MAGEA3), in Combination With Immune Modulating Therapy in Patients With Metastatic Melanoma or Previously Treated Cutaneous Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turnstone Biologics, Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turnstone Biologics, Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b open-label dose escalation trial of Ad/MG1-MAGEA3 and Pembrolizumab in&#xD;
      patients with Metastatic Melanoma or Cutaneous Squamous Cell Skin Cancer that has failed&#xD;
      prior standard of care treatments. Upon determination of a Maximum Tolerated Dose (MTD) or&#xD;
      Maximum Feasible Dose (MFD) the study will be expanded into up to 24 additional Metastatic&#xD;
      Melanoma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b open-label dose escalation trial of Ad/MG1-MAGEA3 and Pembrolizumab in&#xD;
      patients with Metastatic Melanoma or Cutaneous Squamous Cell Skin Cancer that has failed&#xD;
      prior standard of care treatments. This study will consist of two arms where the dose will be&#xD;
      increased independently until the maximum tolerated dose (MTD) / maximum feasible dose (MFD)&#xD;
      is reached.&#xD;
&#xD;
      Arm 1 - Low-dose cyclophosphamide, followed by an Ad-MAGEA3 intramuscular (IM) prime,&#xD;
      followed by intravenous (IV) administration of MG1-MAGEA3 and IV pembrolizumab.&#xD;
&#xD;
      Arm 2 - Ad-MAGEA3 IM injection as a prime, followed by IV administration of MG1-MAGEA3,&#xD;
      followed by intratumoral (IT) injection of MG1-MAGEA3 into tumors and IV pembrolizumab.&#xD;
&#xD;
      In the Phase 1b Expansion for each arm, additional patients will be enrolled at the MTD/MDF&#xD;
      as determined in Phase 1 in order to more thoroughly explore immune response,&#xD;
      pharmacokinetics/dynamics, and safety for Malignant Melanoma patients who have failed&#xD;
      standard therapies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    insufficient suitable drug supply&#xD;
  </why_stopped>
  <start_date type="Actual">February 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Ad/MG1-MAGEA3 administration in Melanoma or Squamous Cell Skin Carcinoma</measure>
    <time_frame>6 months</time_frame>
    <description>Safety will be determined by assessing the severity and frequency of treatment emergent Adverse Events and clinical laboratory toxicity using NCI CTCAE v 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose (MTD)/ maximum feasible dose (MFD) of Ad/MG1-MAGEA3 in Melanoma or Squamous Cell Skin Carcinoma</measure>
    <time_frame>5 weeks</time_frame>
    <description>MTD/MFD of Ad/MG1-MAGEA3 administered by IV infusion alone and IV infusion followed by direct injection of tumor (IT injection) in Melanoma or Squamous Cell Skin Carcinoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate Overall Response</measure>
    <time_frame>2 years</time_frame>
    <description>Determine the overall response rate (Partial Response (PR) + Complete Response (CR))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Disease Control</measure>
    <time_frame>2 years</time_frame>
    <description>Determine Disease Control Rate (PR+CR+Stable Disease (SD))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate PFS</measure>
    <time_frame>2 years</time_frame>
    <description>Progression free survival in months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Duration of Response, if any</measure>
    <time_frame>2 years</time_frame>
    <description>Duration of Response (CR, PR, SD) in months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Metastatic Melanoma</condition>
  <condition>Squamous Cell Skin Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm 1: Intravenous Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose cyclophosphamide (300mg/ m2) at Day -3, then a fixed dose of Ad-MAGEA3 administered IM on study Day 1. Followed by one of 3 dose levels (escalation) of MG1-MAGEA3 administered as 2 intravenous (IV) doses at Day 15 and Day 18 and fixed dose pembrolizumab (200mg) beginning at either Week 6 or Day 1, depending on the cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Intravenous followed by Intratumoral Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A fixed dose of Ad-MAGEA3 administered IM followed by Pembrolizumab on Day 1. MG1-MAGEA3 administered as an intravenous (IV) dose at Day 15, followed by intratumoral (IT) MG1-MAGEA3 on Day 22, Day 29, and Day 36. IT MG1-MAGEA3 booster injections may be continued every 3 weeks beginning at Day 43 (Week 6).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ad-MAGEA3</intervention_name>
    <description>Adenovirus vaccine expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen</description>
    <arm_group_label>Arm 1: Intravenous Dosing</arm_group_label>
    <arm_group_label>Arm 2: Intravenous followed by Intratumoral Dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MG1-MAGEA3</intervention_name>
    <description>MG1 Maraba oncolytic virus expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen</description>
    <arm_group_label>Arm 1: Intravenous Dosing</arm_group_label>
    <arm_group_label>Arm 2: Intravenous followed by Intratumoral Dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>monoclonal antibody; checkpoint inhibitor of PD1</description>
    <arm_group_label>Arm 1: Intravenous Dosing</arm_group_label>
    <arm_group_label>Arm 2: Intravenous followed by Intratumoral Dosing</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>low-dose chemotherapy</description>
    <arm_group_label>Arm 1: Intravenous Dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have histologically or cytologically confirmed diagnosis of locally advanced&#xD;
             metastatic melanoma or cutaneous squamous cell carcinoma that has failed standard&#xD;
             therapies&#xD;
&#xD;
          -  For patients treated intratumorally, must have a lesion suitable for direct injection&#xD;
             of MG1-MAGEA3&#xD;
&#xD;
          -  Have at least one tumor amenable to biopsy&#xD;
&#xD;
          -  Have measurable disease via RECIST 1.1 criteria&#xD;
&#xD;
          -  Adequate organ function and performance status&#xD;
&#xD;
          -  Additional inclusion criteria present&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with any MAGE-A3 vaccine immunotherapy&#xD;
&#xD;
          -  Prior systemic therapy for cancer within 4 weeks (8 weeks for lung radiation), and has&#xD;
             recovered from chemo-related toxicities to Grade 1 or less&#xD;
&#xD;
          -  Intolerant to prior PD1/PD-L1 therapy&#xD;
&#xD;
          -  Requires use of anti-platelet or anti-coagulant therapy that cannot be safely&#xD;
             suspended for per protocol biopsies or intra-tumoral injections.&#xD;
&#xD;
          -  Known active CNS metastases and/or carcinomatous meningitis.&#xD;
&#xD;
          -  Active autoimmune disease that has required systemic therapy in the past 2 years.&#xD;
&#xD;
          -  Conditions likely to have resulted in splenic dysfunction.&#xD;
&#xD;
          -  Known HIV/AIDS, active HBV or HCV infection.&#xD;
&#xD;
          -  Additional Exclusion criteria exist&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Bernstein, MD</last_name>
    <role>Study Director</role>
    <affiliation>Turnstone Biologics</affiliation>
  </overall_official>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 10, 2018</study_first_submitted>
  <study_first_submitted_qc>December 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2018</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

